Display options
Cite
Dahlmann M, Monks A, Harris ED, et al. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010037.
Dahlmann, M., Monks, A., Harris, E. D., Kobelt, D., Osterland, M., Khaireddine, F., Herrmann, P., Kemmner, W., Burock, S., Walther, W., Shoemaker, R. H., & Stein, U. (2021). Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers, 14(1), . https://doi.org/10.3390/cancers14010037
Dahlmann, Mathias, et al. "Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010037
Dahlmann M, Monks A, Harris ED, Kobelt D, Osterland M, Khaireddine F, Herrmann P, Kemmner W, Burock S, Walther W, Shoemaker RH, Stein U. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers (Basel). 2021 Dec 22;14(1). doi: 10.3390/cancers14010037. PMID: 35008201; PMCID: PMC8750436.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 22;14(1). doi: 10.3390/cancers14010037.

Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.

Cancers

Mathias Dahlmann, Anne Monks, Erik D Harris, Dennis Kobelt, Marc Osterland, Fadi Khaireddine, Pia Herrmann, Wolfgang Kemmner, Susen Burock, Wolfgang Walther, Robert H Shoemaker, Ulrike Stein

Affiliations

  1. Experimental and Clinical Research Center, a Cooperation between the Charité-Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany.
  2. Molecular Pharmacology Laboratory, Leidos Biomedical Research, Inc., FNLCR, Frederick, MD 21702, USA.
  3. Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Invalidenstraße 80, 10117 Berlin, Germany.
  4. Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Building 440, Frederick, MD 21702, USA.
  5. German Cancer Consortium, 69121 Heidelberg, Germany.

PMID: 35008201 PMCID: PMC8750436 DOI: 10.3390/cancers14010037

Abstract

Metastasis is directly linked to colorectal cancer (CRC) patient survival. Wnt signaling through β-catenin plays a key role. Metastasis-inducing S100A4 is a Wnt/β-catenin target gene and a prognostic biomarker for CRC and other cancer types. We aimed to identify S100A4-dependent expression alterations to better understand CRC progression and metastasis for improved patient survival. S100A4-induced transcriptome arrays, confirmatory studies in isogenic CRC cell lines with defined β-catenin genotypes, and functional metastasis studies were performed. S100A4-regulated transcriptome examination revealed the transcriptional cross-regulation of metastasis-inducing S100A4 with Wnt pathway antagonist Dickkopf-1 (DKK1). S100A4 overexpression down-regulated DKK1, S100A4 knock-down increased DKK1. Recombinant DKK1 reduced S100A4 expression and S100A4-mediated cell migration. In xenografted mice, systemic S100A4-shRNA application increased intratumoral DKK1. The inverse correlation of S100A4 and DKK1 was confirmed in five independent publicly available CRC expression datasets. Combinatorial analysis of S100A4 and DKK1 in two additional independent CRC patient cohorts improved prognosis of overall and metastasis-free survival. The newly discovered transcriptional cross-regulation of Wnt target S100A4 and Wnt antagonist DKK1 is predominated by an S100A4-induced Wnt signaling feedback loop, increasing cell motility and metastasis risk. S100A4 and DKK1 combination improves the identification of CRC patients at high risk.

Keywords: DKK1; S100A4; Wnt signaling; colorectal cancer; patient survival

References

  1. Carcinogenesis. 2007 Dec;28(12):2459-66 - PubMed
  2. Br J Cancer. 2002 Feb 1;86(3):409-16 - PubMed
  3. Oncogene. 1997 Jan 23;14(3):331-7 - PubMed
  4. Annu Rev Pathol. 2011;6:479-507 - PubMed
  5. Genome Biol. 2003;4(10):R70 - PubMed
  6. Clin Cancer Res. 2011 Apr 15;17(8):2444-50 - PubMed
  7. Leukemia. 2014 Jan;28(1):15-33 - PubMed
  8. Methods Mol Biol. 2008;468:5-15 - PubMed
  9. Hepatology. 2016 Dec;64(6):2047-2061 - PubMed
  10. Oncogene. 2007 Jan 11;26(2):312-20 - PubMed
  11. Blood. 2012 Mar 8;119(10):2335-45 - PubMed
  12. N Engl J Med. 2003 Dec 25;349(26):2483-94 - PubMed
  13. Mol Cancer. 2015 Feb 14;14:38 - PubMed
  14. Oncogene. 2006 Dec 4;25(57):7531-7 - PubMed
  15. BMC Cancer. 2019 Dec 12;19(1):1210 - PubMed
  16. Am J Pathol. 2010 Feb;176(2):528-35 - PubMed
  17. Clin Cancer Res. 2016 Sep 15;22(18):4698-711 - PubMed
  18. Mol Biol Cell. 2011 Sep;22(18):3344-54 - PubMed
  19. Cancers (Basel). 2020 Jul 30;12(8): - PubMed
  20. Nat Med. 2009 Jan;15(1):59-67 - PubMed
  21. Neoplasia. 2011 Feb;13(2):131-44 - PubMed
  22. Cell. 2016 Mar 24;165(1):45-60 - PubMed
  23. Cancer Sci. 2012 Apr;103(4):828-35 - PubMed
  24. Oncogene. 2004 Nov 4;23(52):8520-6 - PubMed
  25. PLoS Comput Biol. 2014 Jul 24;10(7):e1003731 - PubMed
  26. Clin Exp Metastasis. 2015 Dec;32(8):857-66 - PubMed
  27. PLoS One. 2013 Jul 26;8(7):e70077 - PubMed
  28. Br J Cancer. 2005 Jun 6;92(11):1955-8 - PubMed
  29. Nature. 2001 May 17;411(6835):321-5 - PubMed
  30. Biochem Biophys Res Commun. 2016 Jun 3;474(3):509-514 - PubMed
  31. PLoS One. 2012;7(7):e40955 - PubMed
  32. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  33. Oncotarget. 2014 May 30;5(10):3220-33 - PubMed
  34. Science. 1997 Mar 21;275(5307):1787-90 - PubMed
  35. Anticancer Res. 2008 Sep-Oct;28(5A):2613-23 - PubMed
  36. F1000Res. 2014 Jul 01;3:151 - PubMed
  37. Mol Cancer Res. 2009 Jun;7(6):933-43 - PubMed
  38. Oncotarget. 2012 Aug;3(8):783-97 - PubMed
  39. Genome Biol. 2003;4(5):P3 - PubMed
  40. BMC Genomics. 2014 Jan 28;15:74 - PubMed
  41. Curr Biol. 2001 Jun 26;11(12):951-61 - PubMed
  42. Cell. 2013 Aug 15;154(4):801-13 - PubMed
  43. Gastroenterology. 2006 Nov;131(5):1486-500 - PubMed
  44. Cancer Lett. 2014 May 1;346(2):172-7 - PubMed
  45. Int J Cancer. 2012 Apr 1;130(7):1558-66 - PubMed
  46. Trends Cancer. 2017 Jul;3(7):471-474 - PubMed
  47. Curr Pharm Des. 2013;19(5):841-63 - PubMed
  48. Diagn Pathol. 2013 Nov 04;8:181 - PubMed
  49. Prostate. 2011 May;71(6):615-25 - PubMed
  50. Nat Cell Biol. 2017 Oct;19(10):1274-1285 - PubMed
  51. Int J Colorectal Dis. 2011 Jul;26(7):847-58 - PubMed
  52. J Pathol. 2010 Mar;220(4):475-89 - PubMed
  53. Recent Results Cancer Res. 2007;176:61-80 - PubMed
  54. Nature. 1998 Jan 22;391(6665):357-62 - PubMed
  55. Tumour Biol. 2014 Apr;35(4):3145-54 - PubMed
  56. PLoS One. 2012;7(6):e38422 - PubMed
  57. Eur Rev Med Pharmacol Sci. 2014;18(12):1742-7 - PubMed
  58. Gastroenterology. 2002 Nov;123(5):1478-84 - PubMed
  59. Gen Physiol Biophys. 2009;28 Spec No Focus:F55-64 - PubMed
  60. Oncogene. 2005 Feb 3;24(6):1098-103 - PubMed
  61. Cancer Res. 1996 Dec 1;56(23):5490-8 - PubMed
  62. Oncogene. 2006 Jul 6;25(29):4116-21 - PubMed
  63. Nat Cell Biol. 2001 Jul;3(7):683-6 - PubMed
  64. J Natl Cancer Inst. 2011 Jul 6;103(13):1018-36 - PubMed
  65. Hum Pathol. 1997 Dec;28(12):1396-407 - PubMed
  66. Annu Rev Cell Dev Biol. 2004;20:695-723 - PubMed
  67. Cancer Metastasis Rev. 2012 Jun;31(1-2):163-72 - PubMed

Publication Types

Grant support